The levonorgestrel-releasing intrauterine system may represent an effective treatment option in >85% of endometrial hyperplasia cases, but histologic regression during and/or at the end of treatment does not assure stable recovery. We recommend periodic endometrial samplings for at least the first 2 years of follow-up and long-term clinical surveillance thereafter.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.fertnstert.2010.07.1044 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
State of the art endocrine treatments for patients diagnosed with endometrial cancer in 2025.
Curr Opin Obstet Gynecol
December 2024
Mount Sinai Medical Center, Miami Beach, Florida, USA.
Purpose Of Review: Endometrial cancer (EC) is rising in incidence, particularly in younger, premenopausal women, due to increasing rates of obesity and delayed childbearing. This review evaluates current and emerging endocrine therapies, with a focus on fertility-preserving approaches for early-stage EC and treatment options for advanced or recurrent disease.
Recent Findings: Fertility-sparing endocrine therapies, such as medroxyprogesterone acetate, megestrol acetate, and levonorgestrel-releasing intrauterine devices, achieve high response rates but carry recurrence risks.
Pain scores at the insertion of the levonorgestrel-releasing intrauterine system among paralympic athletes: Findings from Kyleena® Paralympic sport performance study.
Eur J Obstet Gynecol Reprod Biol
December 2024
Universidade Estadual de Campinas (UNICAMP), Brazil.
Reversal of Endometriosis-Induced Unilateral Ureteral Obstruction and Hydronephrosis With Medical Therapy.
Cureus
November 2024
Obstetrics and Gynecology, Hung Vuong Hospital, Ho Chi Minh, VNM.
Endometriosis is a common condition among women of reproductive age worldwide, with the urinary tract being the second most frequently affected extragenital organ system, particularly the bladder and ureters. Ureteral endometriosis (UE) is relatively rare, often asymptomatic, and can lead to progressive renal function loss if not addressed promptly. Early diagnosis and intervention are essential, requiring a high index of suspicion.
View Article and Find Full Text PDFCost-effectiveness of long-acting progestogens versus the combined oral contraceptives pill for preventing recurrence of endometriosis-related pain following surgery: an economic evaluation alongside the PRE-EMPT trial.
BMJ Open
December 2024
Health Economics Unit, Department of Applied Health Science, College of Medicine and Health, University of Birmingham, Birmingham, B15 2TT, UK
Objectives: To evaluate the cost-effectiveness of long-acting progestogens (LAP), including levonorgestrel-releasing intrauterine system (LNG-IUS) and depot-medroxyprogesterone acetate (DMPA), compared with the combined oral contraceptives pill (COCP) in preventing recurrence of endometriosis-related pain postsurgery.
Design: Within-trial economic evaluation alongside a multicentre, pragmatic, parallel-group, open-label, randomised controlled trial (Preventing Recurrence of Endometriosis by means of Long-Acting Progestogen Therapy trial).
Setting: Thirty-four UK hospitals recruiting participants from November 2015 to March 2019.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!